Abstract
Purpose
Pancreatic cancer (PC) is one of the most aggressive malignancies with no effective treatment if diagnosed in advanced stage. Systemic inflammation is a recognized characteristic of cancer progression, and we believe that the understanding of the influence of inflammatory parameters may contribute to therapeutic improvement in PC. Here, we validated the Eosinophil/Lymphocyte Ratio (ELR) together with the Neutrophil/Lymphocyte Ratio (NLR) and their components, as prognostic factors in PC patients treated with chemoradiation.
Methods
A total of 66 consecutive patients (p) diagnosed with PC stage I–III and treated with External Beam Radiotherapy + chemotherapy ± surgery (28p) in our institution from 2007 to 2018 were retrospectively evaluated. The impact of pre-treatment ELR ≥ 0.04, NLR ≥ 1.9, neutrophilia (≥ 7.0 × 10(9)/l), eosinophilia (≥ 0.5 × 10(9)/l) and lymphopenia (< 1.0 × 10(9)/l) on Overall Survival (OS) and Time-to-Progression (TTP) was evaluated both in the entire cohort and separately according to surgical status.
Results
Higher ELR was associated with longer OS and TTP, both in surgically treated and not operable patients. On univariate analysis, elevated ELR was associated with better OS (HR = 0.3, 95% IC 0.13–0.65, p = 0.003), contrarily to neutrophilia (HR = 2.7, 95% IC 1.2–6.5, p = 0.026) and age > 50 years (HR = 2.6, 95% IC 1.03–6.6, p = 0.044), while NLR, lymphopenia and Ca-19.9 were not significant. On multivariate regression, independent prognosticators for OS were: ELR, age and neutrophilia; while for TTP: ELR, neutrophilia, eosinophilia and lymphopenia.
Conclusions
The host’s immune response influences survival outcomes of PC patients and may be of interest for future research.
Similar content being viewed by others
References
National Cancer Institute: SEER Stat Fact Sheets: Pancreatic Cancer. http://seer.cancer.gov/statfacts/html/corp.html. Accessed 28 Dec 2018.
European Cancer Information System: Data Explorer https://ecis.jrc.ec.europa.eu/explorer.php Accessed 9 Jan 2019.
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406. https://doi.org/10.1056/NEJMoa1809775.
Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26(5):56–68. https://doi.org/10.1093/annonc/mdv295(e-update—cancer of the pancreas treatment recommendations. Published: 15 March 2019. Authors: ESMO Guidelines Committee).
Martinez-Bosch N, Vinaixa J, Navarro P. Immune evasion in pancreatic cancer: from mechanisms to therapy. Cancers. 2018;10(1):1–6. https://doi.org/10.3390/cancers10010006.
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218–30. https://doi.org/10.1016/j.critrevonc.2013.03.010.
Dolan RD, Laird BJA, Horgan PG, McMillan DC. The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review. Crit Rev Oncol Hematol. 2018;132:130–7. https://doi.org/10.1016/j.critrevonc.2018.09.016.
Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416–21.
Asaoka T, Miyamoto A, Maeda S, Tsujie M, Hama N, Yamamoto K, Miyake M, Haraguchi N, Nishikawa K, Hirao M, Ikeda M, Sekimoto M, Nakamori S. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Pancreatology. 2016;16(3):434–40. https://doi.org/10.1016/j.pan.2015.10.006.
Asari S, Matsumoto I, Toyama H, Shinzeki M, Goto T, Ishida J, Ajiki T, Fukumoto T, Ku Y. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios. Surg Today. 2016;46:583–92.
Formica V, Morelli C, Ferroni P, Nardecchia A, Tesauro M, Pelicori S, Cereda V, Russo A, Riondino S, Guadagni F, Roselli M. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. Cancer Biomark. 2016;17:335–45.
Sierzega M, Lenart M, Rutkowska M, Surman M, Mytar B, Mataja A, Siedlar M, Kulig J. Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. Ann Surg Oncol. 2017;24:808–15. https://doi.org/10.1245/s10434-016-5634-0.
Ye S, Bai L. Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma. Cancer Manag Res. 2018;10:3405–17. https://doi.org/10.2147/CMAR.S173444.
Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients. Clin Chim Acta. 2018;479:181–9. https://doi.org/10.1016/j.cca.2018.01.024.
Mowbray NG, Griffith D, Hammoda M, Shingler G, Kambal A, Al-Sarireh B. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. HPB (Oxford). 2018;20(5):379–84. https://doi.org/10.1016/j.hpb.2017.12.009.
Giakoustidis A, Neofytou K, Costa Neves M, Giakoustidis D, Louri E, Cunningham D, Mudan S. Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg. 2018;22(3):197–207. https://doi.org/10.14701/ahbps.2018.22.3.197.
Hirata J, Koga T, Nishimura J, Ibayashi H. Pancreatic carcinoma associated with marked eosinophilia: a case report. Eur J Haematol. 1987;39(5):462–6 (PubMed: 3500871).
Cay A, Imamoglu M, Cobanoglu U. Eosinophilic pancreatitis mimicking pancreatic neoplasia. Can J Gastroenterol. 2006;20(5):361–4 (PubMed: 16691304).
Weller PF, Lim K. Human eosinophil-lymphocyte interactions. Mem Inst Oswaldo Cruz Rio de Janeiro. 1997;92:173–82.
Reichman H, Karo-Atar D, Munitz A. Emerging roles for eosinophils in the tumour microenvironment. Trends Cancer. 2016;2:664–75.
Manohar M, Verma AK, Venkateshaiah SU, Mishra A. Significance of eosinophils in promoting pancreatic malignancy. J Gastroenterol Pancreatol Liver Disord. 2017;5(1):1–15. https://doi.org/10.15226/2374-815X/5/1/001109.
Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2017;7(2):e1393134. https://doi.org/10.1080/2162402x.2017.1393134eCollection 2018.
Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in cancer: favourable or unfavorable? Curr Med Chem. 2016;23:650–66.
Holub K, Biete A. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. BMC Cancer. 2018;18(1):1280. https://doi.org/10.1186/s12885-018-5131-x.
Holub K, Biete A (2018) Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients. Clin Transl Oncol. https://doi.org/10.1007/s12094-018-1991-4.
Mihaljevic AL, Michalski CW, Friess H, et al. Molecular mechanism of pancreatic cancer—understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg. 2010;395:295. https://doi.org/10.1007/s00423-010-0622-5.
Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108:914–23.
Wörmann SM, Diakopoulos KN, Lesina M, Algül H. The immune network in pancreatic cancer development and progression. Oncogene. 2013;33:2956. https://doi.org/10.1038/onc.2013.257.
Fest J, Ruiter R, Ikram M, et al. Reference values for white blood-cell-based inflammatory markers in the Rotterdam Study: a population-based prospective cohort study. Sci Rep. 2018;8(1):10566. https://doi.org/10.1038/s41598-018-28646-w.
Budczies, et al. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization (2012). PLoS One. 2012;7(12):e51862.
Funding
There was no specific funding for this study.
Author information
Authors and Affiliations
Contributions
This article was principally written by KH, with review contributions from CC. Both authors have read and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Data availability
The datasets used and/or analysed during the current study are available on reasonable request.
Conflict of interest
No potential conflict of interest to disclose.
Ethics approval
Our study was approved by the Ethical Committee of the Hospital Clinic de Barcelona.
Informed consent
All patients included in the study signed the informed consent for treatment, data processing and publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Holub, K., Conill, C. Unveiling the mechanisms of immune evasion in pancreatic cancer: may it be a systemic inflammation responsible for dismal survival?. Clin Transl Oncol 22, 81–90 (2020). https://doi.org/10.1007/s12094-019-02113-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-019-02113-y